Donors commit to: 

 

105. Work towards reducing disease funding silos for diagnostics in order to encourage and support more comprehensive diagnostic strategies, including person-centred care, diagnostic integration and network optimization. 

 

106. Support improved global and national coordination across donors, including funding mechanisms, pooling procurement volumes in negotiations with diagnostic manufacturers, and other activities.

 

107. Prioritize and re-invigorate paediatric-specific funding for strengthened implementation of HIV and TB diagnostics and support of person-centred diagnostic technologies (ie. point-of-care infant diagnosis, simplified TB sample types). 

 

108. Support current efforts to transition from outright instrument procurement to all-inclusive bundles, or other novel pricing model to ensure in-country harmonization of commodity procurement.

​

109. Support in a transparent manner, including key performance indicators, the procurement of commodities and operational costs to maintain and further scale-up POC infant diagnosis, as well as viral load testing for infants, children, and pregnant and breastfeeding women and advanced HIV disease diagnostics, including TB, as an integral part of optimized and integrated national diagnostic networks and in accordance with national plans and targets.

 

110. Continue (and expand) support to WHO PQ to broaden their mandate as planned and to shorten timelines for review and minimize time to national registration. 

 

Unitaid commits to:

​

123. Continue work on accelerating the availability and affordability of innovative diagnostic tools, including those that benefit children living with HIV, TB and other co-infections – either through funding late-stage development or product adaptations (including sample approaches) that will adapt to the settings these tools are needed. 

​

124. Continue direct support to WHO within the enabler grant for diagnostic activities, as well as direct support to WHO PQR for quality and regulatory priorities.

​

125. Pursue opportunities to strengthen regional manufacturing of diagnostics, as part of Untaid’s new strategy (2023 – 2027).   

​

All partners commit to: 

 

163. Address inequities by tackling the stigma and discrimination in communities, schools, and healthcare settings that prevent children living with HIV from accessing testing and treatment. 

​

164. Increase literacy about CD4 testing and viral load and promote a client-centred approach to support expansion of access to viral load for pregnant and breastfeeding women and children on treatment, including at the point-of-care. 

​

165. Review and assess emerging co-infections for immunocompromised infants and children, including those with advanced HIV disease, such as severe bacterial infections, fungal infections, and others for country consideration and implementation.

​

166. Engage affected communities for input and guidance on investment and programmatic priorities, provide support to in-country civil society organizations to engage in advocacy and demand creation for new tools, and ensure data is publicly available to support communities and civil society to monitor progress regarding uptake and implementation of essential diagnostic tools.

​

 - 

​

​

Unitaid commits to:

​

198. Catalyse the evaluation and uptake of new tools and approaches to reduce the case detection gap through market acceleration, accuracy trials, operational research, and optimised implementation algorithms.

​

199. Support operational and implementation research to increase case-finding through new tools, testing procedures and algorithms, and the scale-up of product procurement in high TB burden countries.

​

200. Continue work on accelerating the availability and affordability of innovative diagnostic tools, including those that benefit children living with HIV, TB and other co-infections – either through funding late-stage development or product adaptations (including sample approaches) that will adapt to the settings these tools are needed. 

​

201. Ensure that catalytic pilots for diagnostic introduction will promote efforts for diagnostic network optimization to accelerate a multi-disease approach, as part of efforts to further integrate laboratory networking and reduce disease silos.

​

202. Continue direct support to WHO within the enabler grant for diagnostic activities, as well as direct support to WHO PQR for quality and regulatory priorities.

 - 

​

​